Introduction
Telomeres are the repetitive DNA:protein complexes at the ends of linear chromosomes, which shorten with every cell division in human somatic cells 1 . Telomere shortening eventually leads to the activation of a DNA damage response and cellular senescence or apoptosis [2] [3] [4] . Germ cells, stem cells and cells in the developing human embryo overcome telomere shortening by expression of the ribonucleoprotein enzyme telomerase [5] [6] [7] [8] .
Telomerase catalyzes addition of telomeric DNA repeats to chromosome ends by reverse transcription of a template sequence within its integral RNA subunit (hTR in humans 9 ). The core active human telomerase complex consists of hTR, the reverse transcriptase protein subunit (hTERT) 10 , and the RNA binding protein dyskerin 11, 12 . Telomerase interacts with many other proteins during its biogenesis and transport to the telomere, such as the protein TCAB1 (also known as WDR79 and WRAP53), which is responsible for trafficking telomerase to nuclear Cajal bodies 13, 14 , and from there to the telomere 15 .
Individuals who inherit extremely short telomeres are at risk of developing one of a group of disorders collectively termed "short telomere syndromes" 16, 17 . The first of these diseases linked to short telomeres was dyskeratosis congenita (DC) 11 , defined by a mucocutaneous triad of abnormal skin pigmentation, oral leukoplakia and nail dystrophy, and characterized by progressive bone marrow failure due to depletion of functional hematopoietic progenitor and stem cells 18 . Patients with DC, or its more severe variants
Revesz syndrome and Hoyeraal-Hreidarsson syndrome, harbor deleterious mutations in the genes encoding dyskerin 19 , hTR 20 , hTERT 21 , TCAB1 22 , the dyskerin-associated proteins Nop10 23 and Nhp2 24 , or the telomere-binding proteins TIN2 25, 26 , CTC1 27, 28 and RTel1 [29] [30] [31] [32] .
Patients with acquired or familial aplastic anemia, but lacking the other clinical features of DC, can also carry short telomeres and mutations in the genes encoding hTR 33 or hTERT 21, 34 .
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The telomere-binding protein TPP1 (encoded by the gene adrenocortical dysplasia homolog (mouse) [ACD] , and previously known as PTOP, PIP1 or TINT2) is critical for telomere stability and length regulation [35] [36] [37] [38] . TPP1 binds to the telomere via interaction with TIN2, and in turn tethers the single-stranded DNA binding protein Pot1 to telomeres [36] [37] [38] .
TPP1 is required for Pot1 to perform its role in protecting telomeres from being recognized as DNA damage [39] [40] [41] . The Pot1/TPP1 heterodimer also has a separate role in promoting the processivity of telomerase, i.e. its ability to synthesize long tracts of telomeric DNA 42 . A region on the surface of TPP1 known as the TEL patch mediates this interaction with telomerase, and is necessary for the recruitment of telomerase to telomeres [43] [44] [45] [46] .
Here we identify a family with three generations of individuals with short telomeres and aplastic anemia or other related blood disorders, all of whom carry a heterozygous mutation in the ACD/TPP1 gene. This mutation results in an in-frame deletion of an amino acid in the TEL patch of TPP1, and we demonstrate that the mutated TPP1 protein is able to localize to telomeres but fails to recruit telomerase to telomeres. These data support a causal relationship between this TPP1 mutation and disease in this family.
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Methods
Subjects
The proband presented to Children's Hospital Westmead, Australia with severe thrombocytopenia and macrocytosis, and has been diagnosed with aplastic anemia. Her family history includes other cases of bone marrow failure, as well as oral carcinoma and leukemia ( Figure 1A , Table 1 ). Peripheral blood DNA was available from the proband, her parents and maternal grandparents. Informed consent was obtained from all participating individuals, in accordance with the Declaration of Helsinki, and the studies were approved by the Human Research Ethics Committee of the Sydney Children's Hospitals Network.
Whole exome sequencing and bioinformatics
The procedure was described elsewhere 47 . Briefly, exonic regions were captured using Agilent SureSelect Human All Exon kit, and pair-end sequencing was carried out on Illumina
HiSeq 2000 machines. The Illumina pipeline at default settings was applied to process raw image files for base-calling and generating raw sequencing read files in fastq format.
Subsequently, two independent analysis workflows were used to perform sequencing read alignment, variant calling and variant annotation (supplemental Table 1 ). In the first pipeline, Burrows-Wheeler alignment was used to align fastq files to the human reference genome (UCSC hg19) 48 . Then variants were called using Genome Analysis Tool Kit (GATK, version 
Multiple filtering steps and Mendelian genetic analysis
Under an autosomal dominant inheritance, we applied the following mutational filtering steps in both pipelines described above. We first selected heterozygous variants shared by all three affected individuals, and required that those variants should not be found in the proband's unaffected grandfather. Then we eliminated variants which meet either one of the following criteria: a) out of exonic regions, b) synonymous changes, and c) with frequency > 0.5% in dbSNP135 54 , 1000 Genomes Project (n = 1,092 genotyped samples) 55 ,
HapMap Project (n = 1,301 genotyped samples) 56 , NHLBI Exome Sequencing Project (n = 6,500 exomes) (http://evs.gs.washington.edu/EVS/), CAG-CHOP (n = 334 exomes) or BGI (n = 1,414 control exomes) databases. We paid special attention to variants close to splicing sites and frameshift indels. In the next step, we considered evolutionary conservation and filtered the non-conserved regions with PhyloP 57 value < 0.95, then retained variants with "deleterious/damaging" prediction of pathogenicity by PolyPhen 58 and SIFT 59 . Finally, we took into account biological and clinical relevance of the identified variants (supplemental Table 2 ).
PCR and Sanger sequencing
The deletion in ACD/TPP1 (RefSeq: NM_001082486.1) identified through WES was confirmed by Sanger sequencing of DNA from peripheral blood of all available family members, including the three affected individuals and clinically unaffected father and maternal grandfather. The primers TPP1-SeqF and TPP1-SeqR (supplemental Table 3 Unstained duplicate tubes were run in parallel to determine autofluorescence. After 
Patient telomere length analysis (qPCR)
Genomic DNA from peripheral blood samples was used in telomere length analysis by quantitative PCR (qPCR), performed on the Rotor-Gene Q (Qiagen), using Rotor-Gene SYBR Green PCR Master Mix (Qiagen). The assay was similar to that previously 63, 64 . Briefly, telomeric (T) DNA was amplified using Tel1b and Tel2b primers (supplemental Table 3 ), while the single copy gene (S), used to normalize the amount of input DNA, was amplified using the HBG1 and HBG2 primers (supplemental Table 3 ). A standard curve was used to convert the cycle threshold into nanograms of DNA, and relative telomere length calculated as the T/S ratio from the mean of triplicate samples. Values obtained from 240 healthy individuals show the normal percentiles for different age groups.
Detection of endogenous TPP1 mRNA
RNA was extracted from cells using the RNeasy Mini Kit (Qiagen), followed by DNA digestion with DNAseI (Invitrogen). cDNA synthesis was performed with the SuperScript III First Strand Synthesis System for RT-PCR (Invitrogen). To detect expression of the mutant allele, a 400 bp region of ACD/TPP1 spanning the mutation was amplified by PCR using primers TPP1-Fw1 and TPP1-Rv1 (supplemental Table 3 ). Amplification was performed using Platinum®Taq DNA Polymerase (Life Technologies) in an Eppendorf
Mastercycler gradient at 95 °C for 5 min, followed by 36 cycles of 95 °C for 30 s, 60 °C for 45 s, and 72 °C for 45 s. An aliquot of the PCR products was visualized with 1% agarose gel electrophoresis, and the remainder purified using a QIAGEN PCR Purification Kit and digested with restriction enzyme XmnI, followed by 1% agarose gel electrophoresis.
For quantitative RT-PCR (qRT-PCR) of endogenous TPP1 mRNA levels, the primers targeting the 5' UTR of TPP1 (i.e. specific for expression of the endogenous gene) were TPP1-Fw2 and TPP1-Rv2 (supplemental Table 3 ). GAPDH was used as the internal control (supplemental Table 3 ). qRT-PCR was performed using SYBR Green Master Mix 
Fluorescence in situ hybridization (FISH) of hTR and telomeric DNA
Simultaneous FISH against hTR and telomeric DNA was performed as described 15 .
Briefly, harvested synchronized 293T cells were cytospun onto slides, fixed with formaldehyde, and permeabilized. Slides were incubated with five AlexaFluor 488-labeled anti-hTR oligonucleotides (supplemental Table 3 ; Sigma) and a Texas Red-labeled telomere probe (supplemental Table 3 ; Sigma) in FISH hybridization buffer 15 . FISH staining was visualized on a Zeiss AxioImager M1 microscope with a Plan-Apochromat 63× oil objective Standard curves based on the signal of the input samples were used to normalize the amount of telomeric DNA recovered.
Cell lysis and western blot
Harvested synchronized cells were lysed using 4 × Lithium Dodecyl Sulfate (LDS)
buffer ( Imager.
For
Results
Disease phenotype of proband and family
The 18 year-old proband ( Figure 1A , V:1), her mother and maternal grandmother presented with bone marrow failure of varying severity, and their decreasing ages of presentation in successive generations suggested disease anticipation ( Table 1 ). The proband is the only child of non-consanguineous Caucasian parents. She presented at 8 years of age with increasing pancytopenia, having been previously healthy with normal growth and development. Pancytopenia was associated with marked elevation in fetal hemoglobin (31%) and macrocytosis ( Table 1 ). The bone marrow was markedly hypocellular without morphological dysplasia or cytogenetic abnormality, consistent with aplastic anemia. There was no associated facial dysmorphism, or skeletal, cardiac or urogenital tract anomalies. Although the proband's mother ( Figure 1A , IV:2) was diagnosed with myelodysplasia in her early 20s following investigations for thrombocytopenia, she most likely has mild bone marrow failure (Table 1) . She has remained asymptomatic without disease progression or malignant transformation into her mid-40s. She has one unaffected healthy male sibling.
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The proband's maternal grandmother ( Figure 1A , III:6) was investigated for mild macrocytic anemia with variable thrombocytopenia associated with hypocellular bone marrow at 47 years of age. A diagnosis of possible aplastic anemia/myelodysplasia was made and she was monitored without therapy as cytopenia was mild and there were minimal symptoms. Earlier blood counts are not available but parameters at 55 years are shown in Table 1 . She developed carcinoma of the tongue at 59 years of age despite having been a lifelong non-smoker and teetotaler; this was treated with surgery and local radiotherapy only.
Over the ensuing 12 months, there was increasing pancytopenia needing erythrocyte transfusions. Her death at 61 years was attributed to aplastic anemia. This patient's paternal grandfather died from leukemia in his 30s; there were, however, no clinical or hematological data available on this individual.
The proband was screened for mutations in DC genes with autosomal dominant inheritance at the age of 14 years and no mutations were detected in TERC, TERT and TINF2.
She was later retested using whole exome sequencing (performed by the Dyskeratosis Congenita Registry, London) and no significant variants in any of the nine known DC genes were detected. A blood sample referred in 2012 to Repeat Diagnostics (Vancouver, BC, Canada) for telomere length testing showed an average telomere length of less than the 1st percentile (lymphocytes and granulocytes) by Flow-FISH, supporting the diagnosis of DC or a related disorder of telomere length in the proband (unpublished data). The proband and her mother were retested when an in-house Flow-FISH assay was available; mononuclear telomere length was less than the 1st percentile for the proband and around the 5th percentile for her mother ( Figure 1B ). Quantitative PCR (qPCR) analysis of peripheral blood telomere length 63 confirmed these findings, and revealed short telomeres in the affected grandmother, but not in the unaffected father or grandfather ( Figure 1C ). Thus, short telomeres segregate with disease phenotype in this family.
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Genomic variants identified by whole exome sequencing and bioinformatics
We performed Whole Exome Sequencing (WES) on the proband (V:1), her mother (IV:2), and her maternal grandparents (III:5 and III:6) ( Figure 1A) , with each individual's exome covered at least 62 times (supplemental Table 1 ). On average, ~44,000 single nucleotide variants (SNVs) and ~7,000 small insertion-deletions (indels) were called for each exome by pipeline 1 (see Methods), while ~87,000 SNVs and ~6,000 indels were called by pipeline 2. After filtering, over 16,000 SNVs and ~600 indels were retained as qualified for further analysis in pipeline 1 and over 17,000 SNVs and ~700 indels were left in pipeline 2.
We followed an autosomal dominant inheritance and each pipeline generated a list of candidate variants (supplemental Table 2 ). We noticed the overlapping variant of a 3 bp deletion in gene ACD, which encodes the human TIN2-and Pot1-interacting protein (TPP1);
this variant could only be found in the three affected samples and is absent from any public databases (supplemental Table 2 was cleaved in two with Xmn1, whereas approximately half of the RT-PCR product from the patient's cells was not digested with this enzyme ( Figure 2B ). This demonstrates that the WT and ΔK170 TPP1 alleles are expressed equally at the mRNA level in cells from the patient.
TPP1 mutant ΔK170 localizes to telomeres in human cells
Lysine 170 is localized on the surface of the TPP1 protein known as the TEL patch, between two amino acids shown to be vital for binding to telomerase, recruitment of telomerase to telomeres and telomere length maintenance 44 . Substitution of K170 with alanine resulted in a modest reduction in the ability of telomerase to colocalize with TPP1 45 .
To determine whether deletion of this residue could be causing short telomeres and disease in the family of interest, we analyzed the functional impact of deletion of K170 in immortal human cells in culture.
Nearby mutations in TPP1 are known to be "separation of function" mutations, since they disrupt telomerase interactions without affecting the ability of TPP1 to localize to and protect telomeres 44 . To test the hypothesis that ΔK170 TPP1 could localize to telomeres as efficiently as WT TPP1, we transiently transfected plasmids encoding Myc-tagged versions of both proteins into the human embryonic kidney cell line 293T, in the presence of siRNA directed against the 5' untranslated region (UTR) of TPP1 to reduce competition from endogenous TPP1. Western blot analysis of cells harvested 3 days later confirmed equal expression and stability of WT and ΔK170 TPP1 ( Figure 3A) , and quantitative RT-PCR confirmed knockdown of the endogenous gene ( Figure 3B ). We then carried out chromatin immunoprecipitation (ChIP) using an anti-Myc antibody, measuring the amount of recovered telomeric DNA as a measure of TPP1 presence at the telomere ( Figure 3C ). When normalized against the starting amount of telomeric DNA ("input"), the amounts recovered 1 6 with WT and ΔK170 TPP1 were equal ( Figure 3D ). This indicates that WT and ΔK170 TPP1 load onto telomeres at the same density.
TPP1 mutant ΔK170 fails to recruit telomerase to telomeres
To test the hypothesis that ΔK170 TPP1 is unable to recruit telomerase to telomeres despite its telomeric localization, we analyzed the presence of telomerase at the telomere using FISH against hTR and telomeres simultaneously 15 . This was performed in immortal 293T cells expressing endogenous levels of telomerase, since we have found that telomerase overexpression can perturb some telomerase recruitment pathways 15 . The transfected 293T cells were synchronized in S phase using thymidine and aphidicolin prior to FISH (supplemental Figure 1) . As expected, knockdown of endogenous TPP1 reduced the level of telomerase recruitment to telomeres 43 , and this was rescued by expression of siRNA-resistant WT TPP1, confirming that the observed recruitment defect was due to lack of TPP1 ( Figure   4 ). Importantly, the levels of endogenous TPP1 were reduced by ~50% by our siRNA ( Figure   3B ), demonstrating that a telomerase recruitment defect is observable even in the presence of remaining WT protein, as would be the case in the heterozygous patients. As predicted, expression of siRNA-resistant ΔK170 TPP1 was completely unable to rescue telomerase recruitment to telomeres (Figure 4 ).
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DISCUSSION
The role of the TEL patch of TPP1 in mediating the interaction of this protein with telomerase is well established 44, 45 . This interaction is necessary for the recruitment of telomerase to telomeres, but dispensable for the function of TPP1 in protecting telomeres 44 .
Our data confirm that this surface of TPP1 is vital for telomerase recruitment, and provide evidence that interference with this pathway through TPP1 mutation can lead to telomere shortening in humans. This conclusion is compellingly supported by the finding that mutations in hTERT linked to the short telomere disease idiopathic pulmonary fibrosis (IPF) have been shown to abrogate interaction with TPP1 45 .
These data collectively support the hypothesis that a defect in TPP1 renders telomerase unable to maintain telomeres during development and hematopoiesis in the affected family members, leading to short telomeres and progressive bone marrow failure and eventual aplastic anemia. The increasing severity and younger age of onset of symptoms over several generations of this family is consistent with the phenomenon of genetic anticipation, leading to more severe disease in each successive generation 65 . Curiously, however, telomere lengths did not continue to shorten over the three generations of affected females, relative to expected telomere lengths for age ( Figure 1C ). This is consistent with a previous observation of shorter telomeres in the offspring of fathers, but not mothers, with hTERT mutations 66 , suggesting an intriguing paternal influence on telomere length.
In addition to hematological disorders, the clinical history of this family includes oral carcinoma and leukemia. This is supportive of a link between telomere attrition and increased risk of cancer 67 , and is consistent with previous reports of leukemia and other malignancies, including oral carcinoma, in families with aplastic anemia due to mutations in telomerase components 68, 69 . Families with inherited IPF, short telomeres and hTERT mutations also 1 8 frequently contain members with leukemia and other malignancies 66, 70, 71 . It is likely that inherited short telomeres can lead to chromosome fusions and genetic instability, which predisposes to malignancy.
This study represents the first identification of ACD/TPP1 as a disease-causing gene in humans, bringing the number of genes linked to bone marrow failure disorders to ten.
Seven of these genes encode proteins or RNA that are either part of the telomerase complex (hTR, hTERT, dyskerin, Nop10, Nhp2) or involved in telomerase transport to the telomere (TCAB1, TPP1), and the remaining three proteins (TIN2, CTC1, RTel1) are known to be involved in telomere protection. This strongly supports the causative role of telomere shortening or deprotection in the etiology of bone marrow disorders in humans.
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